INSTITUTO MAIMÓNIDES DE INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA

11:00 – 11:15 SWATH-based quantitative proteomics in colorectal cancer.
B. Jiménez Vacas.

11:00 – 11:15 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.


12:15 – 12:30 Tetrahydrocannabinolic acid targets PPARg and its combination in the treatment of prostate cancer.
Ángela María Cano Yuste.


Víctor Amado Torres.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.

12:15 – 12:30 Antitumor effects of the splicing inhibitor Plakinostat in a prostate cancer model.
Rafael Ruiz Montero.

12:15 – 12:30 The role of magnesium in the processes of intracellular calcium signaling.
Julia Vázquez Borrego.

12:15 – 12:30 Non-functioning Pituitary Adenomas.
Víctor Arias de la Rosa.

12:15 – 12:30 Systematic reviews of best methodological quality adherence achieved in clinical trials when their design are not-structured, low readable, and atherothrombotic profile. Jesús Gay Mimbre.

12:15 – 12:30 Novel Central Regulator of Puberty Onset.
Víctor Arias de la Rosa.